Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Von Willebrand factor A domain-containing protein 3A (VWA3A) is a human protein coded by the VWA3A gene, found on chromosome 16. It contains a von Willebrand factor type A (vWA) domain, a structural motif commonly involved in cell adhesion, migration, and formation of multiprotein complexes. VWA3A is identified as a robust, disease- and age-independent marker of ependymal cells in the brain and spinal cord, shown to have a promoter that drives strong, specific transcription in ependyma across species. While associated diseases include intellectual developmental disorder and ataxia-telangiectasia-like disorder 2, VWA3A is not implicated as a drug target and currently has no characterized therapeutic relevance or interacting drugs. It is not considered a validated therapeutic target or receptor. No biomarkers or safety concerns have been established. Its main biological relevance is in cell type identity, specifically for ependymal cells, and its promoter's utility for achieving ependyma-specific gene expression in gene therapy vector design, particularly for neurological applications.
not applicable (no known drug targeting this protein)
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Von Willebrand factor A domain-containing protein 3A (VWA3A).